![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Time to Viral Suppression Does not Impact SVR in Patients
Treated With Glecaprevir/Pibrentasvir for 8 Weeks
|
|
|
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
Christoph Sarrazin1, Jordan J Feld2, Douglas E Dylla3, Sanjeev Arora4, David Victor III5, Yiran B Hu3, Stanley Wang3, Federico J Mensa3, David Wyles6
1JW Goethe University Hospital, Frankfurt, Germany and St. Josefs-Hospital Wiesbaden, Germany; 2Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada; 3AbbVie Inc., North Chicago, Illinois, United States;
4University of New Mexico, Albuquerque, New Mexico, United States; 5Houston Methodist Hospital, Houston, Texas, United States; 6Denver Health Medical Center, Denver, Colorado, United States
![0423181](../images%20/042318/042318-6/0423181.gif)
![0423182](../images%20/042318/042318-6/0423182.gif)
![0423183](../images%20/042318/042318-6/0423183.gif)
![0423184](../images%20/042318/042318-6/0423184.gif)
![0423185](../images%20/042318/042318-6/0423185.gif)
![0423186](../images%20/042318/042318-6/0423186.gif)
![0423187](../images%20/042318/042318-6/0423187.gif)
![0423188](../images%20/042318/042318-6/0423188.gif)
![0423189](../images%20/042318/042318-6/0423189.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|